Pretomanid
Pretomanid is an antimycobacterial medicine used as part of combination therapy for adults with specific forms of drug-resistant pulmonary tuberculosis, including eligible cases of multidrug-resistant or rifampicin-resistant TB. It works by inhibiting mycolic acid production, disrupting the formation of the tuberculosis bacterium’s cell wall, and, under certain conditions, releasing reactive nitrogen species that damage bacterial cells. It is available as oral tablets and is administered in combination with other anti-TB medicines, such as bedaquiline and linezolid, under specialist supervision. Common side effects include nausea, vomiting, headache, abdominal discomfort, and liver enzyme elevations. Important risks include liver toxicity, peripheral neuropathy, and bone marrow suppression, particularly as part of combination regimens. Treatment requires monitoring of liver function, blood counts, and other potential adverse effects throughout therapy.
Pretomanid was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Pretomanid, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Pretomanid from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Pretomanid, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
